Diuretics

Patients receiving diuretics should be observed carefully for development of cardiac arrhythmias.

Patients receiving epinephrine with diuretics should be observed carefully for development of cardiac arrhythmias.

Increased risk of cardiac arrhythmias when used with epinephrine; careful observation required.

Patients on diuretics may experience precipitous reduction of blood pressure within first hour after initial captopril dose, especially if recently started on diuretic therapy or on severe dietary salt restriction.

Diuretics may induce hypokalemia or hypomagnesemia, which can precipitate QT prolongation with droperidol.

Diuretics augment antihypertensive effect and may cause excessive blood pressure reduction, especially if recently instituted. Close medical supervision required after initial dose.

May cause excessive reduction of blood pressure after initiation of enalapril therapy, particularly if diuretic therapy was recently instituted.

Diuretic therapy may cause excessive reduction of blood pressure after enalaprilat initiation. Risk is higher when diuretic therapy was recently instituted.

Patients receiving epinephrine with diuretics should be observed carefully for development of cardiac arrhythmias.

Patients receiving epinephrine with diuretics should be observed carefully for development of cardiac arrhythmias.

Patients receiving epinephrine with diuretics should be observed carefully for development of cardiac arrhythmias.

May cause excessive reduction of blood pressure, especially in patients with intravascular volume depletion. Risk can be minimized by discontinuing diuretic, increasing salt intake, or reducing starting dose.

May decrease blood glucose lowering effect of LANTUS. Dosage increases and increased glucose monitoring may be required.

Initiation of lisinopril in patients on diuretics may result in excessive reduction of blood pressure and hypotensive effects.

Diuretics may cause excessive reduction of blood pressure after initiation of lisinopril therapy, especially if diuretic therapy was recently instituted. Close medical supervision is required.

Diuretic-induced sodium loss may reduce lithium clearance and increase serum lithium concentrations.

Diuretic-induced sodium loss reduces lithium clearance and increases serum lithium concentrations, requiring frequent monitoring and dosage adjustment.

Concomitant administration may potentiate the renal toxicity of mannitol; avoid use if possible.

Excessive drop in blood pressure, especially in patients recently started on diuretics. Bioavailability of perindoprilat reduced with decreased plasma ACE inhibition.

Potassium-depleting agents administered with corticosteroids require close observation for development of hypokalemia.

Possibility of excessive hypotension, especially in patients with recently instituted diuretic therapy.

Diuretics are associated with hyponatremia; concurrent use with 0.9% sodium chloride injection may increase risk of developing hyponatremia.

Diuretics are associated with hyponatremia; concomitant use may increase risk of developing hyponatremia.

Avoid concomitant use due to increased risk of hyponatremia. If unavoidable, closely monitor serum sodium concentrations.

Increased incidence of thrombocytopenia with purpura reported in elderly patients receiving certain diuretics, primarily thiazides.

Diuretics may produce hyperglycemia and lead to loss of blood glucose control. Patient should be closely observed for loss of blood glucose control.

Non-potassium-sparing diuretics may potentiate hypokalemia or ECG changes when combined with albuterol. Monitor potassium levels.

May potentiate hypokalemia or ECG changes. Use with caution.

Aspirin may diminish diuretic effectiveness in patients with renal or cardiovascular disease through inhibition of renal prostaglandins.

Aspirin may diminish the effectiveness of diuretics in patients with renal or cardiovascular disease due to inhibition of renal prostaglandins.

Effectiveness of diuretics may be diminished by aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow and salt/fluid retention.

Excessive drop in blood pressure, especially with recent diuretic initiation. Potassium-sparing diuretics increase hyperkalemia risk.

Non-potassium-sparing diuretics may worsen electrocardiographic changes and/or hypokalemia associated with concomitant beta-agonists. Use with caution.

Codeine may reduce the efficacy of diuretics. Monitor for reduced effect.

Corticotropin may accentuate the electrolyte loss associated with diuretic therapy.

Dextrose Injection can affect fluid and/or electrolyte balance; monitor blood glucose, fluid balance, serum electrolyte concentrations and acid-base balance when used with diuretics.

Monitor for signs of worsening renal function and diuretic efficacy including antihypertensive effects.

NSAIDs reduced the natriuretic effect of diuretics based on clinical studies and post-marketing observations.

Monitor for worsening renal function and reduced diuretic efficacy including antihypertensive effects.

NEXTSTELLIS may reduce the blood glucose lowering effect of anti-diabetic drugs, requiring increased glucose monitoring and dosage adjustment.

Coadministration with diuretics increases urine volume and frequency, enhancing potential for volume depletion. Monitor volume status and renal function.

Coadministration with empagliflozin increases urine volume and frequency, enhancing potential for volume depletion. Monitor volume status and renal function.

Coadministration with empagliflozin increases urine volume and voids, enhancing potential for volume depletion.

Counter pressor effects, increase arrhythmogenic potential, and potentiate hypokalemic effects of epinephrine.

Additional reductions in blood pressure may occur when epoprostenol is administered with diuretics.

Non-potassium-sparing diuretics may worsen electrocardiographic changes and hypokalemia when used with beta-agonists.

May potentiate hypokalemia or ECG changes with formoterol. Use with caution.

Non-potassium-sparing diuretics may worsen electrocardiographic changes and hypokalemia with concomitant beta-agonists. Use with caution.

Diuretics, especially those causing intravascular volume depletion, may cause excessive reduction of blood pressure after initiation of fosinopril therapy. Patient should be observed closely and starting dose may need reduction.

May produce hyperglycemia and lead to loss of control of blood glucose.

May reduce the glucose-lowering effect of glimepiride, leading to worsening glycemic control.

Tend to produce hyperglycemia and may lead to loss of control. Patient should be closely observed for loss of control when initiated or hypoglycemia when withdrawn.

Diuretics may potentiate hypokalemia or ECG changes with formoterol. Use with caution.

May cause electrolyte imbalance; caution advised with haloperidol decanoate as hypokalemia, hypomagnesemia, and hypocalcemia increase QT prolongation risk.

Drugs that cause electrolyte imbalance; caution advised due to risk of hypokalemia and hypomagnesemia which increase QT prolongation risk with haloperidol.

Hydrocodone may reduce the efficacy of diuretics. Monitor for reduced effect.

Hydrocodone may reduce the efficacy of diuretics. Monitor for reduced effect.

Hydrocodone may reduce the efficacy of diuretics. Monitor for reduced effect.

Ibuprofen may reduce the effect of diuretics; diuretics can increase the risk of nephrotoxicity of NSAIDs in dehydrated patients. Monitor renal function.

May decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.

May decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

May decrease blood glucose-lowering effect; dosage increases and increased glucose monitoring may be required.

May decrease blood glucose lowering effect of insulin detemir. Dosage increases and increased glucose monitoring may be required.

May decrease the blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

May decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.

May decrease blood glucose lowering effect; dose adjustment and increased glucose monitoring may be required.

May decrease the blood glucose lowering effect. Dose adjustment and increased frequency of glucose monitoring may be required.

May decrease blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.

Non-potassium sparing diuretics can worsen ECG changes and hypokalemia caused by beta-agonists. Monitor potassium levels.

Non-potassium-sparing diuretics may worsen ECG changes or hypokalemia when combined with beta-agonists, especially at higher doses. Consider monitoring potassium levels.

Non-potassium-sparing diuretics may have worsening ECG changes or hypokalemia when combined with beta-agonists. Monitor potassium levels during coadministration.

Non-potassium-sparing diuretics may worsen electrocardiographic changes and hypokalemia associated with levalbuterol. Consider monitoring potassium levels.

Concomitant use may cause blood glucose disturbances including hyperglycemia and hypoglycemia. Careful monitoring of blood glucose is recommended.

Opioids can reduce diuretic efficacy by inducing antidiuretic hormone release.

Diuretic-induced sodium loss may reduce lithium clearance and increase serum lithium concentrations. Recommend frequent monitoring and dosage adjustment.

Diuretics induce renal losses of magnesium.

Diuretics induce renal losses of magnesium, potentially leading to hypomagnesemia.

Excessive reductions in blood pressure may occur when ACE inhibitors are started in patients on diuretic therapy. Risk can be minimized by discontinuing diuretics or cautiously increasing salt intake before initiation.

Non-potassium-sparing diuretics may potentiate hypokalemia and ECG changes from formoterol. Use with caution.

Opioids can reduce efficacy of diuretics by inducing antidiuretic hormone release. Monitor for diminished diuresis and blood pressure effects.

May potentiate hypokalemic effect of olodaterol. Use with caution.

Aspirin may reduce diuretic effectiveness by inhibiting renal prostaglandins and causing salt and fluid retention.

Opioids can reduce diuretic efficacy by inducing antidiuretic hormone release. Monitor for diminished diuresis and blood pressure effects.

Diuretics increase risk of fluid and electrolyte abnormalities when used with this drug combination. Use caution and consider additional patient evaluations.

Concomitant use may increase risk of hyponatremia. Monitor serum sodium concentrations if use cannot be avoided.

May increase risk of hyponatremia. Monitor serum sodium concentrations if use cannot be avoided.

Addition of a diuretic to prazosin causes additive hypotensive effect; dose reduction and careful titration recommended.

Addition of a diuretic to prazosin causes additive hypotensive effect requiring dose adjustment and careful titration.

Potassium-depleting diuretics used with corticosteroids require close observation for hypokalemia development.

Codeine may reduce the efficacy of diuretics. Monitor for reduced effect.

Codeine may reduce the efficacy of diuretics. Monitor for reduced effect.

Concomitant diuretic therapy, especially recently instituted, may cause excessive reduction of blood pressure after quinapril initiation. Risk can be minimized by discontinuing diuretic or cautiously increasing salt intake.

Acthar Gel may accentuate the electrolyte loss associated with diuretic therapy.

Concomitant use may increase risk of hyponatremia. Avoid use; if unavoidable, closely monitor serum sodium concentrations.

Concomitant use may increase risk of hyponatremia. Monitor serum sodium concentrations.

Diuretics may potentiate hypokalemia or ECG changes when used with olodaterol. Use with caution.

Diuretics can enhance aminoglycoside toxicity by altering serum and tissue concentrations and causing dehydration. Monitor renal function, serum electrolytes, and signs of ototoxicity.

May cause excessive reduction of blood pressure after initiation of trandolapril therapy, especially with recently instituted diuretic therapy.

May cause excessive reduction of blood pressure after initiation of trandolapril therapy. Starting dose of trandolapril should be reduced or diuretic discontinued.

Potassium-depleting agents; patients should be monitored closely for development of hypokalemia when used with corticosteroids.

Patients taking concomitant diuretics may be at higher risk of depressed levels of consciousness.

No drug interactions reported when guanfacine administered together with diuretics in well-controlled studies.

Terazosin added to diuretics in controlled trials with no unexpected interactions observed.